Today announced its first quarter financial results for the three months ended March 31, 2023. For the quarter, the Company generated revenue of $0.779 million, compared to revenue of $0.676 million for the three months ended December 31, 2022. Net loss was $1.8 million, or $0.02 loss per fully diluted common share in Q1 2023 as compared to a $9.5 million net loss, or $0.09 loss per fully diluted common share in Q4 2022. StageZero Life Sciences shares T.SZLS are trading down $0.01 at $0.06.
Stocks in play: StageZero Life Sciences
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/Cisco%20Systems%2C%20Inc_%20magnified%20logo-by%20Pavel%20Kapysh%20via%20Shutterstock.jpg)
